Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other EventsItem 8.01Other Events.
On April 21, 2017, Aclaris Therapeutics, Inc. (the “Company”) sold 635,000 shares of its common stock at a weighted average price per share of $31.50, for aggregate gross proceeds of approximately $20.0 million. The shares were sold through Cowen and Company, LLC (“Cowen”) to a sales agreement with them dated November 2, 2016. Following these sales, the Company may offer and sell additional shares of its common stock having an aggregate offering price of up to approximately $55.0 million from time to time through Cowen to the sales agreement.
About Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Recent Trading Information Aclaris Therapeutics, Inc. (NASDAQ:ACRS) closed its last trading session down -2.01 at 30.22 with 71,547 shares trading hands.